| Godina | Naslov | Autor(i) | Tip rezultata | Mp-kat. |
| 2021 | Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C | Dziadziuszko, R; ...; Andric, Zoran G   ; ...; (broj, koautora 20) | Konferencijski rad | |
| 2022 | Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial | Peters, Solange; ...; Andric, Zoran G ; ...; (broj, koautora 26) | Naučni članak | 21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+ |
| 2023 | Cerebrospinal fluid and MRI analyses of fenebrutinib treatment in multiple sclerosis reveal brain penetration and early reduction of new lesion activity: results from the phase II FENopta study | Bar-Or, Amit; Dufek, Michal; Budinčević, Hrvoje; Drulović, Jelena S. ; Habek, Mario; Hua, Le; Weber, Martin; Thomas, Piia; Napieralski, Julie; Clayton, David;
Kuruvilla, Denison; Qi, Qi; Xu, Yan; Goodyear, Alexandra; Oh, Jiwon;
| Konferencijski rad | |
| 2020 | Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110 | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 21) | Conference Paper | |
| 2023 | Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial | Livingstone, E; Gogas c , H.; Kandolf-Sekulović, Lidija O.; ...; Mijušković, Željko P. ; ...; (broj, koautora 24) | Научни чланак | 21aM21a - Водећи међународни часопис категорије M21a |
| 2025 | Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial | Livingstone, E; ...; Kandolf, Lidija O; ...; (broj, koautora 25) | Naučni članak | 21aM21a - Vodeći međunarodni časopis kategorije M21a |
| 2024 | Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial | Schadendorf, Dirk; ...; Kandolf-Sekulovic, Lidija O; ...; Mijusković, Željko P. ; ...; (broj, koautora 20) | Conference Paper | |
| 2022 | Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF(V600)-positive melanoma: Interim analysis of the ImmunoCobiVem study. | Schadendorf, Dirk; ...; Kandolf-Sekulovic, Lidija O; ...; Mijuskovic, Željko P ; ...; (broj, koautora 20) | Конференцијски рад | |
| 2023 | Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results | Liu, SV; ...; Andric, Zoran G ; ...; (broj, koautora 24) | Konferencijski rad | |
| 2024 | Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study | Reck, Martin; ...; Andric, Zoran G ; ...; (broj, koautora 24) | Naučni članak | 21M21 - Vodeći međunarodni časopis kategorije M21 |
| 2025 | Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study | O'Shaughnessy, Joyce; ...; Cvetanovic, Ana S; ...; Stamatovic, Ljiljana | Naučni članak | 22M22 - Međunarodni časopis kategorije M22 |
| 2021 | Original Research Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study | O'Shaughnessy, Joyce; ...; Cvetanovic, Ana S; ...; Stamatovic, Ljiljana | Naučni članak | 21aM21a - Vodeći međunarodni časopis kategorije M21a |
| 2020 | Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study | O'Shaughnessy, Joyce; ...; Cvetanovic, Ana; ...; Stamatovic, Ljiljana | Konferencijski rad | |
| 2026 | Real-world prevalence of PD-L1 positivity in early-stage/metastatic triple-negative breast cancer: primary results and pathology insights from the global retrospective observational VANESSA study | D'arrigo, Corrado; ...; Medic-Milijic, Natasa; ...; Popovic, Lazar | Naučni članak | 21aM21a - Vodeći međunarodni časopis kategorije M21a |
| 2020 | Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial | Mansfield, AS; ...; Andric, Zoran G ; ...; (broj, koautora 19) | Naučni članak | 21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+ |
| 2026 | Treatment patterns and clinical outcomes according to PD-L1 status in >2000 patients with early-stage or metastatic triple-negative breast cancer treated in the real-world setting: VANESSA study results | Popovic, Lazar ; Barroso-Sousa, Romualdo; El Saghir, Nagi; Dent, Rebecca; Tuzlali, Sitki; Akhtar, Saad; ...; (broj, koautora 18) | Article | |
| 2021 | Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC | Jassem, Jacek; ...; Andric, Zoran G ; ...; (broj, koautora 19) | Article | |
| 2024 | Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer (ESSCLC) treated with atezolizumab (atezo) | Kao, SCH; Reck, M; Liu, SV; Dziadziuszko, R; Hochmair, MJ; Huemer, F; Gilberto, de Castro J; Bernabe, Caro R; Kim, SH; Kowalski, DM;
Andric, Zoran G ; Oancea, M; Kaul, M; Li, H; Danner, B; Lee, MC; Nabet, BY; Sugawara, S; | Konferencijski rad | |